UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

Abstract The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months. However, resistance often occurs, largely limits its efficacy. Sorafenib was found to target...

Full description

Bibliographic Details
Main Authors: Junjie Xu, Lin Ji, Yeling Ruan, Zhe Wan, Zhongjie Lin, Shunjie Xia, Liye Tao, Junhao Zheng, Liuxin Cai, Yifan Wang, Xiao Liang, Xiujun Cai
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-021-00594-4

Internet

https://doi.org/10.1038/s41392-021-00594-4

Similar Items